MADRID, June 24, 2017 /PRNewswire/ --
Hodgkin lymphoma is the most common malignancy of young adults.
Intensive chemotherapy with eight or six cycles of
eBEACOPP is very effective in patients with advanced-stage
Hodgkin's lymphoma (HL), albeit at the expense of severe
toxicities. Aiming at better tolerability, we investigated whether
metabolic response determined by positron emission tomography after
two cycles (PET-2) would allow us to select patients, who could be
treated with reduced intensity (four cycles) without loss of
efficacy.
(Logo:
http://mma.prnewswire.com/media/524821/EHA_Logo.jpg )
The GHSG HD18 trial was conducted in five European countries
(Germany, Switzerland (SAKK), Austria (AGMT), Czech Republic, the
Netherlands). Between 05/2008 and 07/2014, 2101 patients
aged 18-60 years with newly diagnosed, advanced-stage HL were
recruited, of whom 1005 were PET-2 negative.
Reduced therapy with four cycles of eBEACOPP was
non-inferior to 6/8 cycles in terms of five-year progression-free
survival (92·2% versus 90·8%, difference +1·4%, 95% CI -2·7-5·4).
We observed no treatment related mortality in the experimental
group, fewer infections, less organ toxicities and a very low
incidence of second acute myeloid leukemia. Overall, this resulted
in a significantly superior five-year overall survival (97·7%
versus 95·4%, log-rank p=0·004) for the patient cohort with reduced
treatment.
In conclusion, treatment with four cycles of eBEACOPP in
patients with negative PET-2 is extremely effective, very safe,
short (12 weeks), and affordable. Results for efficacy and safety
compare favorably with any other published treatment strategy.
We therefore recommend PET-2-guided eBEACOPP for patients with
advanced-stage HL.
Presenter: Dr Peter Borchmann
Affiliation: Uniklinik Koeln, Cologne, Germany
Topic: TREATMENT REDUCTION IN PATIENTS WITH
ADVANCED-STAGE HODGKIN LYMPHOMA AND NEGATIVE INTERIM PET: FINAL
RESULTS OF THE INTERNATIONAL, RANDOMIZED PHASE 3 TRIAL HD18 BY THE
GERMAN HODGKIN STUDY GROUP
Abstract S150 will be presented by Peter
Borchmann on Friday, June 23
15:45 - 17:00 in Hall A.
About the EHA Annual Congress
Hematology is a specialty that covers everything to do with
blood: its origin in the bone marrow, diseases of blood and their
treatments. The latest data on research and developments will be
presented. The topics range from stem cell physiology and
development, to leukemia, lymphoma, myeloma - diagnosis and
treatment; red blood cells, white blood cells- and platelet
disorders; thrombosis and bleeding disorders.
SOURCE European Hematology Association